Effects of Probucol on Atherosclerosis of apoE-Deficient or LDL Receptor-Deficient Mice

The effect of probucol on atheroma formation was evaluated using mouse models for atherosclerosis with different diet protocols. Dietary administration of probucol (0.5 %, wt/wt) for 12 weeks reduced total plasma cholesterol levels in both apolipoprotein E (apoE)-deficient mice fed a western diet and in low-density lipoprotein receptor (LDLR)-deficient mice fed a Paigen diet by 60 % and 30 % to 60 %, respectively. Probucol treatment also significantly reduced high-density lipoprotein (HDL) levels in apoE-deficient mice, but not in LDLR-deficient mice. Atherosclerotic plaques in the aortic sinus of probucol-treated apoE-deficient mice were two-fold larger than those in untreated apoE-deficient mice, while the lesions in probucol-treated LDLR-deficient mice were similar to those in untreated LDLR-deficient mice. A strong negative correlation between HDL cholesterol levels and lesion sizes at the aortic sinus was observed in apoE-deficient mice, but not in LDLR-deficient mice. Thus, in contrast to LDLR-deficient mice, probucol had a strong proatherogenic effect in the aortic sinus of apoE-deficient mice associated with the reduction of HDL levels in spite of the reduction of total plasma cholesterol levels. The varying effects of probucol on atherogenesis depend upon the portion of aorta and which animal model is evaluated, implicating that complex cellular events are involved in the effect of probucol.

Hypercholesterolemia - Disease Model - Hypocholesterolemic Agent

References

• 1 Schwartz C J, Valente A J, Sprague E A, Kelley J L, Nerem R M. The pathogenesis of atherosclerosis: an overview.  Clin Cardiol. 1991;  14 I1-I16
• 2 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s.  Nature. 1993;  362 801-809
• 3 Parthasarathy S, Young S G, Witztum J L, Pittman R C, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein.  J Clin Invest. 1986;  77 641-644
• 4 Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty.  Am Heart J. 1996;  132 23-29
• 5 Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S, Seki A, Kato K, Nishimura S, Kanoh T, Yamaguchi H. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial.  J Am Coll Cardiol. 1997;  30 855-862
• 6 Tardif J C, Côté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, Guise P. Probucol and multivitamines in the prevention of restenosis after coronary angioplasty.  N Engl J Med. 1997;  337 365-372
• 7 Rodés J, Côté G, Lespérance J, Bourassa M G, Doucet S, Bilodeau L, Bertrand O F, Harel F, Gallo R, Tardif J C. Prevention of restenosis after angioplasty in small coronary arteries with probucol.  Circulation. 1998;  97 429-436
• 8 Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia.  Am J Cardiol. 1986;  7 29H-35H
• 9 Walldius G, Erikson U, Olsson A G, Bergstrand L, Hådell K, Johansson J, Kaijser L, Lassvik C, Mölgaard J, Nilsson S, Schäfer-Elinder L, Stenport G, Holme I. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).  Am J Cardiol. 1994;  74 875-883
• 10 Regnström J, Walldius G, Nilsson S, Schäfer-Elinder L, Johansson J, Mölgaard J, Holme I, Olsson A G, Nilsson J. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.  Atherosclerosis. 1996;  125 217-229
• 11 Witztum J L. Murine models for study of lipoprotein metabolism and atherosclerosis.  J Clin Invest . 1993;  92 536-537
• 12 Breslow J L. Mouse models of atherosclerosis.  Science. 1996;  272 685-688
• 13 Zhang S H, Reddick R L, Piedrahita J A, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.  Science (Wash. DC). 1992;  258 468-471
• 14 Plump A S, Smith J D, Hayek T, Aaito-Setälä K, Walsh A, Verstuyft J G, Rubin E M, Breslow J L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.  Cell. 1992;  71 343-353
• 15 Ishibashi S, Goldstein J L, Brown M S, Herz J, Burns D. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice.  J Clin Invest. 1994;  93 1885-1893
• 16 Reddick R L, Zhang S H, Maeda N. Atherosclerosis in mice lacking apo E: evaluation of lesional development and progression.  Arterioscler. Thromb1994;  14 141-147
• 17 Nakashima Y, Plump A S, Raines E W, Breslow J L, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.  Arterioscler Thromb. 1994;  14 133-140
• 18 Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.  Proc Natl Acad Sci USA. 1987;  84 5928-5931
• 19 Nagano Y, Nakamura T, Matsuzawa Y, Cho M, Ueda Y, Kita T. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit-long term antiatherogenic effect and effects on established plaques.  Atherosclerosis. 1992;  92 131-140
• 20 Braesen J H, Beisiegel U, Niendolf A. Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits.  Virchows Archiv. 1995;  426 179-188
• 21 Kogushi M, Tanaka H, Ohtsuka I, Yamada T, Kobayashi H, Saeki T, Takada M, Hiyoshi H, Yanagimachi M, Kimura T, Yoshitake S, Saito I. Anti-atherosclerotic effect of E5324, an inhibitor of acyl-CoA: cholesterol acyltransferase, in Watanabe heritable hyperlipidemic rabbits.  Atherosclerosis. 1996;  124 203-210
• 22 Rio M D, Chulia T, Ruiz E, Tejerina T. Action of probucol in arteries from normal and hypercholesterolaemic rabbits.  Br J Pharmacol. 1996;  118 1639-1644
• 23 Sasahara M, Raines E W, Chait A, Carew T E, Steinberg D, Wahl P W, Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol.: I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?.  J Clin Invest. 1994;  94 155-164
• 24 Daugherty A, Zweifel B S, Shonfeld G. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits.  Br J Pharmacol. 1991;  103 1013-1018
• 25 Stein Y, Stein O, Delplanque B, Fesmire J D, Lee D M, Alaupovic P. Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels.  Atherosclerosis. 1989;  75 145-155
• 26 Zhang S H, Reddick R L, Avdievich E, Surles L K, Jones R G, Reynolds J B. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.  J Clin Invest. 1997;  99 2858-2866
• 27 Bird D A, Tangirala R K, Fruebis J, Steinberg D, Witztum J L, Palinski W. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice.  J Lipid Res. 1998;  39 1079-1090
• 28 Shimada M, Ishibashi S, Inaba T, Yagyu H, Harada K, Osuga J, Ohhashi K, Yazaki Y, Yamada N. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase.  Proc Natl Acad Sci USA. 1996;  93 7242-7246
• 29 Piedrahita J A, Zhang S H, Hagaman J R, Oliver P M, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells.  Proc Natl Acad Sci USA. 1992;  89 4471-4475
• 30 Ishibashi S, Brown M S, Goldstein J L, Gerard R D, Hammer R E, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery.  J Clin Invest. 1993;  92 883-893
• 31 Paigen B, Morrow A, Holmes P A, Mitchell D, Williams R A. Quantitative assessment of atherosclerotic lesions in mice.  Atherosclerosis. 1987;  68 231-240
• 32 Fellin R, Gasparotto A, Valerio G, Baiocchi M R, Padrini R, Lamon S, Vitale E, Baggio G, Crepaldi G. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia.  Atherosclerosis. 1986;  59 47-56
• 33 Parthasarathy S, Young S G, Witztum J L, Pittman R C, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein.  J Clin Invest. 1986;  77 641-644
• 34 Elinder L S, Hådell K, Johansson J, Mølgaard J, Holme I, Olsson A G, Walldius G. Probucol treatment decreases serum concentrations of diet-derived antioxidants.  Arterioscler Thromb Vasc Biol. 1995;  15 1057-1063
• 35 Gordon D J, Rifkind B M. High-density lipoprotein: the clinical implications of recent studies.  N Engl J Med. 1989;  321 1311-1316
• 36 Watson A D, Berliner J A, Hama S Y, La Du B N, Faull K F, Fogelman A M, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein.  J Clin Invest. 1995;  96 2882-2891
• 37 Pászty C, Maeda N, Verstuyft J, Rubin E M. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.  J Clin Invest. 1994;  94 899-903
• 38 Plump A S, Scott C J, Breslow J L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in apolipoprotein E-deficient mouse.  Proc Natl Acad Sci USA. 1994;  91 9607-9611
• 39 Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, Sirtori C R. Mechanisms of HDL reduction after probucol: changes in HDL subfractions and increased reverse cholesteryl ester transfer.  Arteriosclerosis. 1989;  9 462-469
• 40 McPherson R, Hogue M, Milne R W, Tall A R, Marcel Y L. Increase in plasma cholesteryl ester transfer protein during probucol treatment: relation to changes in high density lipoprotein composition.  Arterioscler Thromb. 1991;  11 476-481
• 41 Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda T, Harada K, Katsuki M, Yazaki Y, Yamada N. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall.  J Clin Invest. 1995;  95 469-476
• 42 Hoshida S, Yamashita N, Igarashi J, Aoki K, Kuzuya T, Hori M. Long-term probucol treatment reverses the severity of myocardial injury in Watanabe heritable hyperlipidemic rabbits.  Arterioscler Thromb Vasc Biol. 1997;  17 2801-2807
• 43 Kaneko M, Hayashi J, Saito I, Miyasaka N. Probucol downregulates E-selectin expression on cultured human vascular endothelial cells.  Arterioscler Thromb Vasc Biol. 1996;  16 1047-1051
• 44 Johnson R C, Chapman S M, Dong Z M, Ordovas J M, Mayadas T N, Herz J, Hynes R O, Schaefer E J, Wagner D D. Absence of P-selectin delays fatty streak formation in mice.  J Clin Invest. 1997;  99 1037-1043
• 45 Dong Z M, Chapman S M, Brown A A, Frenette P S, Hynes R O, Wagner D D. The combined role of P- and E-selectins in atherosclerosis.  J Clin Invest. 1998;  102 145-152